How Does Regulation Impact Strategic Repositioning by Firms Across Submarkets? Evidence from the Indian Pharmaceutical Industry

References

• Adbi A , Bhaskarabhatla A , Chatterjee C (2018) Stakeholder orientation and market impact: Evidence from India. J. Bus. Ethics 161:479–496.Crossref, Google Scholar
• Adbi A , Chatterjee C , Drev M , Mishra A (2019) When the big one came: A natural experiment on demand shock and market structure in India’s influenza vaccine markets. Production Oper. Management 28(4):810–832.Crossref, Google Scholar
• Anton J , Gertler P (1988) External markets and regulation. J. Public Econom. 37(2):243–260.Crossref, Google Scholar
• Argyres N , Bigelow L , Nickerson J (2015) Dominant designs, innovation shocks, and the follower’s dilemma. Strategic Management J. 36(2):216–234.Crossref, Google Scholar
• Argyres N , Mahoney JT , Nickerson JA (2019) Strategic responses to shocks: Comparative adjustment costs and repositioning in response to shocks. Strategic Management J. 40(3):357–376.Crossref, Google Scholar
• Armstrong M , Sappington D (2006) Regulation, competition and liberalization. J. Econom. Lit. 44(2):325–366.Crossref, Google Scholar
• Armstrong M , Sappington D (2007) Recent developments in the theory of regulation. M. Armstrong M Porter R, eds. Handbook of Industrial Organization, vol. 3 (North-Holland, Amsterdam), 1557–1700.Google Scholar
• Aubert C , Pouyet J (2006) Incomplete regulation, market competition and collusion. Rev. Econom. Design 10(2):113–142.Crossref, Google Scholar
• Ayres I , Braithwaite J (1992) Partial-industry regulation: A monopsony standard for consumer protection. Calif. Law Rev. 80(1):13–53.Crossref, Google Scholar
• Azoulay P (2002) Do pharmaceutical sales respond to scientific evidence? J. Econom. Management Strategy 11(4):551–594.Crossref, Google Scholar
• Bal A (1986) Distortions in drug policy: Who is to be blamed? Econom. Polit. Weekly 21(23):1029–1032.Google Scholar
• Baron D , Myerson R (1982) Regulating a monopolist with unknown costs. Econometrica 50(4):911–930.Crossref, Google Scholar
• Bar-Nahum Z , Finkelshtain I , Kan I (2018) On the effectiveness of price-ceiling regulations: The case of fluid-milk market in Israel. Discussion Paper 290055, Department of Agricultural Economics and Management, Hebrew University of Jerusalem, Jerusalem.Google Scholar
• Bate R , Jin GZ , Mathur A (2015) Falsified or substandard? Assessing price and non‐price signals of drug quality. J. Econom. Management Strategy 24(4):687–711.Crossref, Google Scholar
• Benner MJ , Waldfogel J (2016) The song remains the same? Technological change and positioning in the recorded music industry. Strategy Sci. 1(3):129–147.Link, Google Scholar
• Bennett D , Yin W (2019) The market for high-quality medicine: Retail chain entry and drug quality in India. Rev. Econom. Statist. 101(1):76–90.Crossref, Google Scholar
• Berndt ER , Cockburn IM (2014) The hidden cost of low prices: Limited access to new drugs In India. Health Affairs 33(9):1567–1575.Crossref, Google Scholar
• Bhaskarabhatla A (2018) Regulating Pharmaceutical Prices in India: Policy Design, Implementation, and Compliance (Springer International Publishing, Basel, Switzerland).Crossref, Google Scholar
• Bhaskarabhatla A , Chatterjee C (2017) The role of physicians in prescribing irrational fixed-dose combination medicines in India. Soc. Sci. Med. 174:179–187.Crossref, Google Scholar
• Bhaskarabhatla A , Chatterjee C , Karreman B (2016) Hit where it hurts: Cartel policing using targeted sales and supply embargoes. J. Law Econom. 59(4):805–846.Crossref, Google Scholar
• Bhaskarabhatla A , Chatterjee C , Anurag P , Pennings E (2017) Mitigating regulatory impact: The case of partial price controls on metformin in India. Health Policy Planning 32(2):194–204.Google Scholar
• Bottazzi G , Dosi G , Lippi M , Pammolli F , Riccaboni M (2001) Innovation and corporate growth in the evolution of the drug industry. Internat. J. Indust. Organ. 19(7):1161–1187.Crossref, Google Scholar
• Braeutigam R , Panzar J (1989) Diversification incentives under ‘price-based’ and ‘cost-based’ regulation. RAND J. Econom. 20(3):373–391.Crossref, Google Scholar
• Brennan T , Palmer K (1994) Comparing the costs and benefits of diversification by regulated firms. J. Regulatory Econom. 6(1):115–136.Crossref, Google Scholar
• Brick IE , Jagpal HS (1981) Monopoly price-advertising decision-making under uncertainty. J. Indust. Econom. 29(3):279–285.Crossref, Google Scholar
• Busenbark J , Wiseman R , Arrfelt M , Woo H-S (2017) A review of the internal capital allocation literature: Piecing together the capital allocation puzzle. J. Management 43(8):2430–2455.Crossref, Google Scholar
• Calzolari G , Scarpa C (2016) Conglomerates and regulation. Econom. Inquiry 54(3):1648–1669.Crossref, Google Scholar
• Chang YM , Warren J (1997) Allocative efficiency and diversification under price-cap regulation. Inform. Econom. Policy 9(1):3–17.Crossref, Google Scholar
• Chaudhuri S (1986) Drug policy. Econom. Polit. Weekly 21(51):2199–2200.Google Scholar
• Chernew M , Cooper Z , Larsen-Hallock E , Scott Morton F (2018) Are healthcare services shoppable? Evidence from the consumption of lower-limb MRI scans. NBER Working Paper 24869, National Bureau of Economic Research, Cambridge, MA.Google Scholar
• Chintagunta P , Vilcassim N (1994) Marketing investment decisions in a dynamic duopoly: A model and empirical analysis. Internat. J. Res. Marketing 11(3):287–306.Crossref, Google Scholar
• Crawford G , Shum M (2005) Uncertainty and learning in pharmaceutical demand. Econometrica 73(4):1137–1173.Crossref, Google Scholar
• David G , Markowitz S , Richards-Shubik S (2010) The effects of pharmaceutical marketing and promotion on adverse drug events and regulation. Amer. Econom. J. Econom. Policy 2(4):1–25.Crossref, Google Scholar
• de Figueiredo JM , Silverman BS (2007) Churn, baby, churn: Strategic dynamics among dominant and fringe firms in a segmented industry. Management Sci. 53(4):632–650.Link, Google Scholar
• DeJong C , Aguilar T , Tseng CW , Lin GA , Boscardin WJ , Dudley RA (2016) Pharmaceutical industry-sponsored meals and physician prescribing patterns for Medicare beneficiaries. JAMA Intern. Med. 176(8):1114–1122.Crossref, Google Scholar
• Dehez P , Jacquemin A (1975) A note on advertising policy under uncertainty and dynamic conditions. J. Indust. Econom. 24(1):73–78.Crossref, Google Scholar
• Dey S (2014) GSK Consumer fined for overcharging. Business Standard (May 28), https://www.business-standard.com/article/companies/gsk-consumer-fined-for-overcharging-114052800299_1.html Google Scholar
• Dobrev S , Kim TY (2006) Positioning among organizations in a population: Moves between market segments and the evolution of industry structure. Admin. Sci. Quart. 51(2):230–261.Crossref, Google Scholar
• Dorfman R , Steiner PO (1954) Optimal advertising and optimal quality. Amer. Econom. Rev. 44(5):826–836.Google Scholar
• DPCO (2013) Gazzette Notification of Drug Price Control Order 2013 (Department of Pharmaceuticals, Government of India, New Delhi, India).Google Scholar
• Fiocco R (2012) Competition and regulation with product differentiation. J. Regulatory Econom. 42(3):287–307.Crossref, Google Scholar
• Gal M (2001) Reducing rival’s prices: Government-supported mavericks as new solutions for oligopoly pricing. Stanford J. Law Bus. Finance 7(1):73–102.Google Scholar
• Gaynor M , Ho K , Town RJ (2015) The industrial organization of health-care markets. J. Econom. Lit. 53(2):235–284.Crossref, Google Scholar
• George LM , Waldfogel J (2006) New York Times and the market for local newspapers. Amer. Econom. Rev. 96(1):435–447.Google Scholar
• Gimeno J , Chen MJ , Bae J (2006) Dynamics of competitive repositioning: a multidimensional approach. Adv. Strategic Management. 23:399–441.Crossref, Google Scholar
• Greve HR (1996) Patterns of competition: The diffusion of a market position in radio broadcasting. Admin. Sci. Quart. 41:29–60.Crossref, Google Scholar
• Gupta SK , Nayak RP , Sivaranjani R (2016) A study on the interactions of doctors with medical representatives of pharmaceutical companies in a tertiary care teaching hospital of South India. J. Pharmacy Bioallied Sci. 8(1):47–51.Crossref, Google Scholar
• Hastings J , Hortaçsu A , Syverson C (2017) Sales force and competition in financial product markets: The case of Mexico’s social security privatization. Econometrica 85(6):1723–1761.Crossref, Google Scholar
• Hindu Business Line (2007) Pharma industry opposes price control mechanism. The Hindu Business Line (January 10), https://www.thehindubusinessline.com/todays-paper/Pharma-industry-opposes-price-control-mechanism/article20152247.ece.Google Scholar
• Horowitz I (1970) A note on advertising and uncertainty. J. Indust. Econom. 18(2):151–160.Crossref, Google Scholar
• Howard-Hassmann R (2015) The right to food under Hugo Chávez. Human Rights Quart. 37(4):1024–1045.Crossref, Google Scholar
• Klepper S , Thompson P (2006) Submarkets and the evolution of market structure. RAND J. Econom. 37(4):861–886.Crossref, Google Scholar
• Knittel C , Stango V (2003) Price ceilings as focal points for tacit collusion: Evidence from credit cards. Amer. Econom. Rev. 93(5):1703–1729.Crossref, Google Scholar
• Kyle MK (2007) Pharmaceutical price controls and entry strategies. Rev. Econom. Statist. 89(1):88–99.Crossref, Google Scholar
• Lambin J , Naert P , Bultez A (1975) Optimal marketing behavior in oligopoly. Eur. Econom. Rev. 6(2):105–128.Crossref, Google Scholar
• Levitt SD , Syverson C (2008) Market distortions when agents are better informed: The value of information in real estate transactions. Rev. Econom. Statist. 90(4):599–611.Crossref, Google Scholar
• Lewis T , Sappington D (1989) An informational effect when regulated firms enter unregulated markets. J. Regulatory Econom. 1(1):35–46.Crossref, Google Scholar
• Macher JT , Wade JB (2017) The black box of strategy: Competitive responses to and performance from adverse regulatory events. Working paper, Georgetown University, Washington, DC.Google Scholar
• Macher JT , Miller NH , Osborne M (2018) Innovation-based repositioning: An empirical application in cement. Presentation, Sumantra Ghoshal Conference, London Business School, London, June 10–11.Google Scholar
• Malerba F , Orsenigo L (2002) Innovation and market structure in the dynamics of the pharmaceutical industry and biotechnology: Toward a history‐friendly model. Indust. Corporate Change 11(4):667–703.Crossref, Google Scholar
• Menon AR , Yao D (2017) Elevating repositioning costs: Strategy dynamics and competitive interactions. Strategic Management J. 38(10):1953–1963.Crossref, Google Scholar
• Miraldo M (2009) Reference pricing and firms’ pricing strategies. J. Health Econom. 28(1):176–197.Crossref, Google Scholar
• Mizik N , Jacobson R (2004) Are physicians “easy marks”? Quantifying the effects of detailing and sampling on new prescriptions. Management Sci. 50(12):1704–1715.Link, Google Scholar
• Mujumdar S , Pal D (2005) Do price ceilings abroad increase US drug prices? Econom. Lett. 87(1):9–13.Crossref, Google Scholar
• Mudur G (2013) Doctors in India defy guidelines on generic drugs. BMJ 347:f4244.Crossref, Google Scholar
• Natividad G (2013) Financial capacity and discontinuous investment: Evidence from emerging market multibusiness firms. Rev. Financial Stud. 26(9):2375–2410.Crossref, Google Scholar
• Natividad G , Rawley E (2016) Interdependence and performance: A natural experiment in firm scope. Strategy Sci. 1(1):12–31.Link, Google Scholar
• Neu W (1993) Allocative inefficiency properties of price-cap regulation. J. Regulatory Econom. 5(2):159–182.Crossref, Google Scholar
• Nickerson JA , Silverman BS (2003) Why firms want to organize efficiently and what keeps them from doing so: Inappropriate governance, performance, and adaptation in a deregulated industry. Admin. Sci. Quart. 48(3):433–465.Crossref, Google Scholar
• NMRA (2016) Maximum Retail Prices of 48 Selected Medicinal Product Formulations-2016 (National Medicines Regulatory Authority, Ministry of Health, Nutrition & Indigenous Medicine, Sri Lanka).Google Scholar
• NPPA (2015) Compendium of Prices (National Pharmaceutical Pricing Authority, Government of India, New Delhi, India).Google Scholar
• PharmaBiz.com (2006) Drugs costing less than Rs 5 a day for patients may be taken out of price control. PharmaBiz.com (January 2), http://www.pharmabiz.com/NewsDetails.aspx?aid=31214&sid=2.Google Scholar
• Porter M (1991) Toward a dynamic theory of strategy. Strategic Management J. 12(SI):95–117.Google Scholar
• Roy V , Rana P (2018) Prescribing generics: All in a name. Indian J. Med. Res. 147(5):442–444.Crossref, Google Scholar
• Sappington D (2003) Regulating horizontal diversification. Internat. J. Indust. Organ. 21(3):291–315.Crossref, Google Scholar
• Seamans R , Zhu F (2014) Responses to entry in multi-sided markets: The impact of Craigslist on local newspapers. Management Sci. 60(2):476–493.Link, Google Scholar
• Seamans R , Zhu F (2018) Repositioning and cost-cutting: The impact of competition on platform strategies. Strategy Sci. 2(2):83–99.Link, Google Scholar
• Sengul M , Almeida Costa A , Gimeno J (2019) The allocation of capital within firms. Acad. Management Ann. 13(1):43–83.Crossref, Google Scholar
• Shaver JM (2019) Interpreting interactions in linear fixed-effect regression models: When fixed-effect estimates are no longer within-effects. Strategy Sci. 4(1):25–40.Link, Google Scholar
• Singh K (2011) New drug policy draft faces public heat. Economic Times (December 19), https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/new-drug-policy-draft-faces-public-heat/articleshow/11162212.cms?from=desktop.Google Scholar
• Sorensen A (2000) Equilibrium price dispersion in retail markets for prescription drugs. J. Polit. Econom. 108(4):833–850.Crossref, Google Scholar
• Spurling GK , Mansfield PR , Montgomery BD , Lexchin J , Doust J , Othman N , Vitry AI (2010) Information from pharmaceutical companies and the quality, quantity, and cost of physicians’ prescribing: A systematic review. PLoS Med. 7(10):e1000352.Crossref, Google Scholar
• Sutton J (1998) Technology and Market Structure. Theory and History (MIT Press, Cambridge, MA).Google Scholar
• Task Force on Pharmaceutical Pricing (2005) Task force to explore options other than price control for achieving the objective of making available life-saving drugs at reasonable prices. Report, Department of Chemicals and Petrochemicals, Government of India, New Delhi, India.Google Scholar
• Tripsas M (2008) Customer preference discontinuities: A trigger for radical technological change. Management Decision Econom. 29(2-3):79–97.Crossref, Google Scholar
• Uzunca B (2018) A competence-based view of industry evolution: The impact of submarket convergence on incumbent−entrant dynamics. Acad. Management J. 61(2):738–768.Crossref, Google Scholar
• Uzunca B , Cassiman B (2018) Entry diversion: Entry barriers to divert submarket entry. Acad. Management Proceed. 2018(1):17793.Crossref, Google Scholar
• Venkataraman S , Stremersch S (2007) The debate on influencing doctors’ decisions: Are drug characteristics the missing link? Management Sci. 53(11):1688–1701.Link, Google Scholar
• Waldman D , Jensen E (2013) Industrial Organization: Theory and Practice , 4th ed. (Pearson, London).Google Scholar
• Wang RD , Shaver JM (2014) Competition-driven repositioning. Strategic Management J. 35(11):1585–1604.Crossref, Google Scholar
• Wang RD , Shaver JM (2016) The multifaceted nature of competitive response: Repositioning and new product launch as joint response to competition strategy science. Strategy Sci. 1(3):148–162.Link, Google Scholar